OMTX-705

N/A

Report date: 2025/05/14 14:10:40
First In Class

Base Information

Drug NameOMTX-705
Drug Alias NameAnti-FAPα:Cytolysin ADCOMTX-705
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > TAM470 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsFibroblast activation protein alpha antagonists
TargetsTubulinProlyl endopeptidase FAP
Therapy Area/IndicationsSolid tumoursAdenocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpainMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOncomatryx Biopharma Sl
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInxMed (Hong Kong) LtdOncomatryx Biopharma SlInxmed (nanjing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursAdenocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A